Research Article
A Liver Stiffness Measurement-Based Nomogram Predicts Variceal Rebleeding in Hepatitis B-Related Cirrhosis
Table 2
Clinical characteristics between the rebleeding and nonrebleeding groups.
| | No rebleeding () | Rebleeding () | value |
| | Age (years) | 49.82 (12.99) | 53.17 (12.09) | 0.055 | | Male | 149 (68.66) | 53 (73.61) | 0.379 | | BMI | 21.86 (3.04) | 22.4 (3.13) | 0.193 | | Portal vein diameter (cm) | 1.4 (1.3-1.6) | 1.5 (1.3-1.6) | 0.100 | | Use of NSBB | 155 (71.4) | 34 (47.2) | <0.001 | | Baseline LSM (kPa) | 13.3 (9.89-16.9) | 18.8 (13.5-23.4) | <0.001 | | WBC (×109/L) | 4.65 (2.28) | 3.48 (2.08) | <0.001 | | HB (g/L) | 103 (27.7) | 88.9 (24.7) | <0.001 | | Platelet count (×109/L) | 104 (74.4) | 65.9 (38.4) | <0.001 | | PT (second) | 13.4 (12.5-14.8) | 14.0 (12.7-14.8) | 0.235 | | INR | 1.19 (1.10-1.33) | 1.25 (1.14-1.34) | 0.058 | | Fibrinogen (g/L) | 1.81 (1.37-2.34) | 1.56 (1.16-1.93) | 0.012 | | Albumin (g/L) | 35.0 (6.29) | 35.1 (5.42) | 0.826 | | Total bilirubin | 18.9 (12.3-31.9) | 20.0 (13.7-28.8) | 0.974 | | ALT (U/L) | 21.0 (15.8-31.8) | 25.0 (17.0-45.0) | 0.07 | | AST (U/L) | 31.5 (22.8-47.5) | 36.0 (27.0-55.0) | 0.043 | | Cr (μmol/L) | 5.98 (5.25) | 5.65 (5.02) | 0.634 | | BUN (mmol/L) | 65.0 (56.0-77.2) | 6.2 (55.3-80.6) | 0.887 | | MELD score | 9.07 (8.13-11.4) | 9.54 (8.31-11.3) | 0.151 | | Child-Pugh class | | | 0.229 | | A | 205 (70.9%) | 56 (19.7%) | | | B | 12 (4.2%) | 16 (5.2%) | |
|
|
value < 0.05 indicates a significant difference between the cohorts presenting with rebleeding event versus no rebleeding. BMI: body mass index; HB: hemoglobin; WBC: white blood cell; PVT: portal vein thrombosis; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: gamma-glutamyl transpeptidase; LSM: liver stiffness measurement; INR: international normalized ratio; Cr: creatinine BUN: blood urea nitrogen; PT: prothrombin time. |
